The call, on record
TMDX bullish call
Quoted text as recorded“You want to just buy these companies and hold them long term. Let them do their thing and compound.”@ 17:19 · open at this moment on YouTube ↗
Our interpretation
- Source published
- Jun 29, 2026
- Timeframe
- hold long term
- Interpreted confidence
- medium
- Specificity
- vague
Email me when TMDX calls resolve
When a tracked TMDX call is scored — hit, miss or partial — we’ll email you the result. No account needed.
Used only for these updates. Privacy
Our summary of the thesis
BullishStructured interpretation of the video, not a verbatim quotation. Check the source for conditions, emphasis and context.
The host sees TransMedics as an attractively valued, profitable growth company and endorses buying and holding businesses like it to compound over time. It remains on his watchlist while he prepares further research.
Key arguments
- The business makes organ transplants viable for more patients.
- Historical revenue growth has been strong.
- New devices could expand the addressable market.
- The host considers its valuation attractive following a large drawdown.
- He compares its development stage with Intuitive Surgical years earlier.
Counter-arguments acknowledged
- The stock is volatile and substantially below its all-time high.
- Growth and operating leverage have softened recently.
- Slowing growth may explain the falling share price.
- The host does not own shares and plans additional coverage.
Hedges and caveats (from the video)
- Tenfold upside is presented as potential, not a guaranteed return.
- SoFi and TransMedics are volatile stocks.
- Hims & Hers has experienced slowing growth and reduced profitability while investing in expansion.
- Toast faces a difficult restaurant industry environment.
- The host does not yet own Toast or TransMedics in the Asymmetric Portfolio.
- TransMedics growth and operating leverage have recently softened.
About this record
Not yet reviewed by a moderatorImported analysis · scheduled AI source. A quote, summary and outcome each need their own context. Moderator review does not certify investment performance.
- Source published
- Jun 29, 2026, 1:57 PM UTC
- First recorded by TubeRank
- Nov 1, 2026, 4:27 AM UTC
- Record last updated
- Nov 1, 2026, 4:27 AM UTC
- Moderator review recorded
- Not recorded
- Transcript provenance
- YouTube captions (manual or automatic)
- Recorded analysis processor/source label
- codex-cli-scheduled
- This can identify a workflow rather than an exact AI model version.
- Submission path version
- manual_v1
- Identifies the precomputed submission path. It does not identify an AI model version or imply human authorship.
- Outcome methodology version
- Not recorded; not audited under current rules
Recent record changes 1 shown
Nov 1, 2026, 4:27 AM UTC
source updated
- Recorded analysis processor/source label
BeforeNot recorded
Aftercodex-cli-scheduled
- Extraction or submission version
BeforeNot recorded
Aftermanual_v1
Showing up to 20 recent changes. The complete feed has 2 recorded events for this call, including its initial entry. Read the full paginated history (JSON); follow nextCursor while hasMore is true.
Stored outcome evidence
- Stored reference price
- Not recorded
- Not recorded · provider not recorded
- Target as extracted
- Not recorded
- Stated deadline as extracted
- None recorded
- Recorded outcome date
- Not recorded
- Outcome price observation
- Not recorded
- Not recorded · provider not recorded
Stored explanation
No explanation was recorded for this outcome.
Missing timestamps, providers and versions are historical gaps. Stored observations can include daily closes; they do not show every intraday touch or prove an executable trade. Read the methodology.
Why we interpreted the confidence this way
In the TransMedics discussion, the host explicitly endorses buying and holding for compounding, but supplies no price target and has not initiated a position.